Logo

KLTOW

Klotho Neurosciences, Inc.

KLTOW

Klotho Neurosciences, Inc. • NASDAQ
$0.14 ▲ 15.76% (+0.02)
Market Cap $37.04 M
52w High $0.17
52w Low $0.13
Dividend Yield 0%
P/E 0
Volume 3.35K
Outstanding Shares 256.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.853M ▼ $-2.896M ▲ 0% $-0.049 ▼ $-1.718M ▲
Q2-2025 $0 $1.893M ▲ $-4.093M ▼ 0% $0 ▲ $-2.333M ▼
Q1-2025 $0 $1.587M ▼ $-2.234M ▼ 0% $-0.081 ▼ $-1.68M ▲
Q4-2024 $0 $1.852M ▼ $-2.067M ▲ 0% $-0.076 ▲ $-1.771M ▲
Q3-2024 $0 $2.871M $-2.959M 0% $-0.18 $-2.914M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.348M ▼ $10.073M ▼ $145.891K ▼ $9.927M ▼
Q2-2025 $8.431M ▲ $10.846M ▲ $195.409K ▼ $10.65M ▲
Q1-2025 $565.869K ▲ $2.987M ▲ $2.349M ▲ $638.709K ▼
Q4-2024 $63.741K ▲ $2.457M ▼ $1.272M ▲ $1.185M ▼
Q3-2024 $50.895K $2.464M $1.004M $1.461M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.896M ▲ $-1.088M ▲ $0 $5.3K ▼ $-1.083M ▼ $-1.088M ▲
Q2-2025 $-4.093M ▼ $-1.968M ▼ $0 $9.834M ▲ $7.865M ▲ $-1.968M ▼
Q1-2025 $-2.234M ▼ $-1.554M ▼ $0 $2.056M ▲ $502.128K ▲ $-1.554M ▼
Q4-2024 $-2.067M ▲ $-944.154K ▲ $0 $957K ▲ $12.846K ▲ $-944.154K ▲
Q3-2024 $-2.959M $-1.073M $0 $278.518K $-794.441K $-1.073M

Five-Year Company Overview

Income Statement

Income Statement Klotho Neurosciences is a classic early‑stage biotech: effectively no product revenue yet and a small but real operating loss. Earnings per share have been negative and have recently moved further into the red, reflecting the cost of development work without offsetting sales. This is typical for a company still in the clinical stage, but it does mean the story is entirely about future potential rather than current profitability.

Balance Sheet

Balance Sheet The reported balance sheet data is essentially blank, so public figures here are not very informative. In practical terms, a company at this stage usually has a relatively light asset base, with value concentrated in intellectual property and R&D rather than physical assets. The main questions for investors tend to be: how much cash the company has, how long that cash can support operations, and whether it relies on new share issuances or partnerships for funding. Without clear balance sheet detail, there is more uncertainty around financial strength and dilution risk.

Cash Flow

Cash Flow Cash flow information is also not meaningfully disclosed in the data provided. Conceptually, Klotho is almost certainly using cash rather than generating it, as is standard for a clinical‑stage biotech with no commercial products. The key cash flow risks are: the pace of R&D spending, manufacturing scale‑up costs for gene therapies, and the timing and terms of any capital raises or collaboration payments. The business model will likely remain cash‑consuming until at least one program gains approval and commercialization, which is inherently a long and uncertain path.

Competitive Edge

Competitive Edge Klotho’s competitive position rests on a specialized, differentiated scientific focus rather than on current market share. It targets the Klotho “longevity” protein with gene therapy for serious neurodegenerative diseases, where medical need is high and existing treatments are limited. Exclusive global licenses, patent protection in major regions, and Orphan Drug Designation in ALS provide a meaningful intellectual property and regulatory shield. At the same time, the company is small and operates in disease areas crowded with large, well‑funded pharma and biotech players using diverse approaches, which raises competitive pressure if the science succeeds but also underscores the size of the opportunity.

Innovation and R&D

Innovation and R&D Innovation is clearly the centerpiece of Klotho Neurosciences. The company is developing gene therapies that boost a secreted form of the Klotho protein using viral vectors designed for durable, one‑time treatment. Preclinical work suggests broad neuroprotective effects—reducing inflammation and oxidative stress, promoting nerve repair, and helping clear toxic proteins tied to aging and dementia. The pipeline is still early but focused: one program in Alzheimer’s, another in ALS moving toward human trials, and companion diagnostic tools to measure Klotho activity. Partnerships for manufacturing and a proposed acquisition of cellular rejuvenation technologies indicate an ambition to build a broader longevity platform, but all of this comes with high scientific, regulatory, and execution risk typical of frontier biotech.

Summary

KLTOW is an early, science‑driven biotech with no commercial revenue yet and growing R&D‑driven losses, as you would expect for a company still in the clinical phase. Its story centers on a distinctive therapeutic concept—gene therapy based on the Klotho “anti‑aging” protein—aimed at very difficult neurodegenerative diseases such as ALS and Alzheimer’s. Strong intellectual property, Orphan Drug status, and a focused pipeline are clear strengths. The flip side is high uncertainty: limited financial disclosure in the data provided, dependence on external capital, complex gene therapy manufacturing, and the usual binary risks of clinical trials. The investment case is therefore less about current financial performance and more about whether the upcoming trial milestones, partnerships, and funding decisions can steadily de‑risk a novel but inherently speculative platform.